Skip to main content
. Author manuscript; available in PMC: 2023 Mar 24.
Published in final edited form as: ACS Biomater Sci Eng. 2020 Nov 20;8(10):4140–4152. doi: 10.1021/acsbiomaterials.0c01313

Table 1.

Mass Loading, Release, and Activity of IgA2 Antibody in Polymer-Coated Porous Si Particle Formulations

polymer coating dissolution mediuma intended release region IgA2 loadingb (%) release 3h @ pH 6.8/7.4c(%) preserved activityd (%)
Eudragit S100 SGF→PBS colon (pH >7) 29 ± 1 70 ± 7 44 ± 10
Eudragit L100 SGF→PBS small intestine (pH > 5.5) 29 ± 1 61 ± 2 21 ± 6
SGF→FasSIF 48 ± 2 32 ± 13
Eudragit L30 D-55 SGF→PBS small intestine (pH > 5.5) 31 ± 2 56 ± 2 20 ± 6
SGF→FasSIF 41 ± 3 24 ± 11
a

SGF is simulated gastric fluid, pH = 1.2; PBS is phosphate buffered saline solution, pH 7.4; FasSIF is fasting state simulated intestinal fluid, pH = 6.8.

b

Mass loading of IgA2 protein in the porous Si carrier, prior to polymer coating; defined as (mass of IgA2)/(mass of IgA2 + pSi carrier), given as a percentage. Errors are 3 SD.

c

Percent by mass of IgA2 released from the particle formulation into the indicated release medium, after 3 h of exposure. Measured by BCA assay. Errors given are 3 SD.

d

Activity of IgA2 measured by both ELISA and HIV neutralization assay as percent of total IgA2 released, after 3 h of exposure to the pH 6.8/7.4 solution, corresponding to the 5 h time point in Figure 2. Errors given are 3 SD.